Get your full text copy in PDF
Haixiao Wu, Alexey V. Germanov, Galina L. Goryaeva, Alexander N. Yachmenev, Dmitriy I. Gordienko, Victor V. Kuzin, Alexander V. Skoroglyadov
(Department of Orthopaedics, Pirogov Russian National Research Medical University, Moscow, Russian Federation)
Med Sci Monit 2016; 22:1403-1409
Intra-articular adhesion is one of the common complications of post knee surgery and injury. The formation of joint adhesion can lead to serious dysfunction. Rosuvastatin (ROS) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, with multiple biological effects. In our study, the object was to evaluate the effectiveness of ROS in the prevention of post-operative knee adhesion in rats.
MATERIAL AND METHODS: Femoral condyle exposing surgery was performed on 45 healthy Sprague Dawley rats. Gelatin sponges soaked with 20 mg/kg of ROS, 10 mg/kg of ROS, or saline were used to cover the surgical site. The post-operative knee joints were fixed in a flexed position with micro Kirschner wires for four weeks. ROS effectiveness for treating intra-articular adhesion was determined with visual score evaluation, hydroxyproline content, histological analyses, immunohistochemistry, and inflammatory and vascular endothelial growth factors expression.
RESULTS: The animals’ recovery was stable after surgery. The hydroxyproline content, visual score, and inflammatory vascular growth factors expression levels suggested that, compared with the control group, the ROS treatment groups showed better outcomes. ROS prevented joint adhesion formation, collagen deposition, and vascularization at the surgical site, and also inhibited inflammatory activity post-operatively. Compared with the 10 mg/kg ROS group, the 20 mg/kg ROS group showed significantly better outcomes.
CONCLUSIONS: The local application of ROS reduced intra-articular adhesion formation, collagen deposition, and vascularization at the surgical site, and inhibited inflammatory activity post-operatively. These results suggested optimal concentration of ROS to be 20 mg/kg.
Keywords: Cicatrix - pathology, Animals, Administration, Topical, Fibroblasts - pathology, Interleukin-6 - metabolism, Knee Joint - pathology, RNA, Messenger - metabolism, Rats, Sprague-Dawley, Rosuvastatin Calcium - therapeutic use, Tissue Adhesions - prevention & control, Vascular Endothelial Growth Factor A - metabolism